Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

EXS73565

Small molecule · developed by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals

Phase 1 Most advanced trial
RXRX Developer
1 Registered trials

What is EXS73565?

EXS73565 is an orally administered agent studied in relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, and Waldenstrom's macroglobulinemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Oncology
Developer
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. (RXRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06980116 Phase 1 Relapsed or Refractory B-cell Malignancies Recruiting RXRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diffuse-large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Marginal Zone Lymphoma (MZL)Relapsed or Refractory B-cell MalignanciesWaldenstrom's Macroglobulinemia (WM)

More from Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the RXRX page.

Follow RXRX, the company behind EXS73565

See RXRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RXRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.